Delving into the Latest Updates on Iodine[I-125] with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Therapeutic radiopharmaceuticals

Synonyms-

Target-

Action-

Mechanism

Ionising radiation emitters

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaI

InChIKeyZCYVEMRRCGMTRW-YPZZEJLDSA-N

CAS Registry14158-31-7

A retrospective analysis was conducted on patients with radioiodine-refractory thyroid carcinoma (RRTC) who underwent radioactive 125I seed implantation combined with anlotinib from January 2019 to October 2024 at Jiangxi Cancer Hospital. Data on tumor size changes before and after treatment, serological tests (including serum TG, TgAb, CTn, CEA, etc.), changes in patients' pain scores, and side effects were collected to evaluate the clinical efficacy and safety of this therapy.

Start Date01 Jan 2019

Sponsor / Collaborator

Jiangxi Provincial Cancer Hospital

NL-OMON37110

/ CompletedPhase 2IIT

Prospective multi-centre study of low-dose Iodine125 (I-125) prostate brachytherapy performed after transurethral resection. PROBATE study - I125 postTURP

Start Date08 Aug 2013

Sponsor / Collaborator-

JPRN-jRCT1051180150

/ CompletedNot Applicable

Clinical efficay focusing on I-125 salvage permanent brachytherapy in men diagnosed prostate cancer who recurred after external beam therapy

Start Date22 Aug 2012

Sponsor / Collaborator-

100 Clinical Results associated with Iodine[I-125]

Login to view more data

100 Translational Medicine associated with Iodine[I-125]

Login to view more data

100 Patents (Medical) associated with Iodine[I-125]

Login to view more data

5,233

Literatures (Medical) associated with Iodine[I-125]

01 May 2025·Marine Pollution Bulletin

Spatial-temporal variations of kelp 129I contents in coastal waters of China before and after the Fukushima Daiichi Nuclear Power Plant accident

Article

Author: Ge, Baozhu ; Yang, Xiaoqi ; Liu, Jialin ; Zhang, Luyuan ; Zhuang, Shuhan ; Sun, Xiaole ; Xie, Guozhi ; Liu, Xiaowen ; Sun, Weidong ; Zhao, Chang ; Qiao, Fangli ; Fan, Yukun ; Fang, Sheng ; Liu, Qi ; Duan, Delin

Radioactive ¹²⁹I isotope, as one of the main products of the nuclear fission process, can be applied to track radioactive substances in the environment. So far, limited studies have investigated the spatial-temporal distribution of ¹²⁹I in marine ecosystems including the ¹²⁹I isotope released via nuclear activities. This study reports the ¹²⁹I concentrations of kelps collected from the shallow coastal Yellow Sea and East China Sea from 2009 to 2021. The results show that the kelp ¹²⁹I concentrations increased by 5 times in our studied areas in 2011 right after the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident and then decreased back to the pre-accident level in the following years. Meanwhile, the kelp ¹²⁹I concentrations in the Yellow Sea decreased much faster than those in the East China Sea between 2012 and 2021, which could be attributed to large river inputs that sustain a high supply of ¹²⁹I to coastal areas. Our observations suggest that the FDNPP accident may not be the cause of the increase in ¹²⁹I in coastal kelps in 2011. Instead, the ¹²⁹I emitted by nuclear fuel reprocessing plants (NFRPs) and being flushed into coastal areas by rivers could be main source of ¹²⁹I to coastal kelps.

02 Apr 2025·ACS Chemical Neuroscience

Comparative Radiotracing Quantifies Brain Cellular Uptake and Catabolism of Bispecific Antibodies Targeting Transferrin Receptor and CD98hc

Article

Author: Bond, Layne G. ; Tessier, Peter M. ; Tripu, Deepika R. ; Veire, Jacob L. ; Greineder, Colin F. ; Lucas, Michael J.

Bispecific antibodies (bAbs) that engage cerebrovascular targets, induce transport across the blood-brain barrier (BBB), and redistribute to secondary targets within the brain parenchyma have the potential to transform the diagnosis and treatment of a wide range of central nervous system disorders. Full understanding of the pharmacokinetics (PK) of these agents, including their potential for delivering cargo into brain parenchymal cells, is a key priority for the development of numerous potential therapeutic applications. To date, the brain PK of bAbs that target transferrin receptor (TfR-1) and CD98 heavy chain (CD98hc) has been characterized using techniques incapable of distinguishing between CNS clearance of intact protein from uptake and catabolism by brain parenchymal cells. Herein, we address this knowledge gap via a comparative radiotracing strategy using two radioisotopes with distinct residualizing properties, iodine-125 (I-125) and zirconium-89 (Zr-89). We first identify reaction conditions for tetravalent chelator modification and Zr-89 radiolabeling that do not adversely affect in vitro or in vivo function. We then use comparative radiotracing to define the PK of TfR-1 and CD98hc targeted bAbs without a parenchymal target, generating quantitative evidence of TfR-1-mediated cellular uptake and catabolism that implicates these processes in previously reported differences in the brain retention of IgGs shuttled across the BBB via these two pathways. Finally, we perform comparative radiotracing on a TfR-1 bAb with an internalizing neuronal target (TrkB), demonstrating rapid divergence of Zr-89 and I-125 PK curves, with a > 30-fold difference in brain content of the two radioisotopes. Together, these results establish comparative radiotracing as a valuable technique for identifying internalizing cellular targets within the brain parenchyma and quantifying the extent and timing of bAb uptake and catabolism following target engagement.

01 Mar 2025·International Journal of Oral and Maxillofacial Surgery

Multimodal image-guided surgical robot versus 3D-printed template for brachytherapy of malignant tumours in the skull base and deep facial region: a clinical comparative study

Article

Author: Lin, Q ; Zhang, H ; Jin, N ; Xing, L ; Meng, F ; Zhu, L

This study compared a multimodal image-guided robot and three-dimensionally (3D) printed templates for implanting iodine-125 (I¹²⁵) radioactive seeds in patients with malignant tumours in the skull base and deep facial region. Seventeen patients who underwent I¹²⁵ radioactive seed implantation between December 2018 and December 2019 were included. The operation time, intraoperative blood loss, and accuracy of seed implantation were compared between the multimodal image-guided robot-assisted implantation (experimental) group (n = 7) and 3D-printed template-assisted implantation (control) group (n = 10). In total, 291 seeds were implanted in the experimental group and 436 in the control group; the mean error of seed implantation accuracy was 1.95 ± 0.13 mm and 1.90 ± 0.08 mm, respectively (P = 0.309). The preparation time was 26.13 ± 5.28 min in the experimental group and 0 min in the control group, while the average operation time was 34.44 ± 6.39 min versus 43.70 ± 6.06 min, respectively. The intraoperative blood loss was 4.96 ± 1.76 ml (experimental) versus 8.97 ± 2.99 ml (control) (P = 0.123). Multimodal image-guided robot-assisted I¹²⁵ radioactive seed implantation met the clinical requirements for treating malignant tumours in the skull base and deep facial regions.

100 Deals associated with Iodine[I-125]

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Iodine[I-125]	V09GB	DB14804

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2014	Not Applicable	-	300	Pd-103	xtherahwai(dmckptfbod) = tbfhnpjupp htebqttppe (yegpqvffgb ) View more	-	01 Feb 2014
ASCO_GU2014	Not Applicable	-	300	I-125	xtherahwai(dmckptfbod) = lnwzhbwzgj htebqttppe (yegpqvffgb ) View more	-	01 Feb 2014
I-125 Treated Prostate Cancer Patients (ASTRO2012)	Not Applicable	Prostatic Cancer	-	I-125 (Preplanned implant using preloaded needles)	alsjzbudud(lfekzaugeg) = ojxzzlfpxa tmlljwcuiy (pumcwojwwe )	Positive	01 Nov 2012
I-125 Treated Prostate Cancer Patients (ASTRO2012)	Not Applicable	Prostatic Cancer	-	I-125 (Intraoperative treatment planning)	alsjzbudud(lfekzaugeg) = vjsjzkiwvt tmlljwcuiy (pumcwojwwe )	Positive	01 Nov 2012
1124 (AUA2012)	Not Applicable	Localized Prostate Carcinoma	267	I-125 (Patients with seed migration)	abqcqwuylb(lmrrxbqsda) = not significantly different sbhuqplqke (zbfgujuqsx )	-	01 Apr 2012
2041 (AUA2010)	Not Applicable	Gleason score \| PSA	560	Low-dose-rate Iodine-125 brachytherapy	(vzbzoudmlv) = ieeczyeptd outifhlmfr (qzqplpkbfj, 75% - 81%) View more	-	01 Apr 2010